Anika Therapeutics Pre-Tax Profit Margin 2006-2021 | ANIK

Anika Therapeutics pre-tax profit margin from 2006 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Anika Therapeutics Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $0.15B $-0.01B -4.83%
2021-06-30 $0.14B $-0.02B -11.68%
2021-03-31 $0.13B $-0.04B -26.92%
2020-12-31 $0.13B $-0.03B -22.14%
2020-09-30 $0.13B $-0.01B -4.69%
2020-06-30 $0.13B $0.02B 11.90%
2020-03-31 $0.13B $0.04B 29.60%
2019-12-31 $0.12B $0.04B 31.30%
2019-09-30 $0.11B $0.04B 36.61%
2019-06-30 $0.11B $0.04B 33.94%
2019-03-31 $0.11B $0.04B 33.64%
2018-12-31 $0.11B $0.02B 21.70%
2018-09-30 $0.11B $0.02B 21.30%
2018-06-30 $0.11B $0.03B 23.15%
2018-03-31 $0.11B $0.03B 28.18%
2017-12-31 $0.11B $0.05B 41.96%
2017-09-30 $0.11B $0.05B 44.64%
2017-06-30 $0.11B $0.05B 47.75%
2017-03-31 $0.11B $0.05B 46.67%
2016-12-31 $0.10B $0.05B 50.00%
2016-09-30 $0.11B $0.06B 52.83%
2016-06-30 $0.10B $0.06B 52.88%
2016-03-31 $0.10B $0.05B 53.00%
2015-12-31 $0.09B $0.05B 51.06%
2015-09-30 $0.09B $0.04B 50.00%
2015-06-30 $0.08B $0.04B 47.62%
2015-03-31 $0.09B $0.04B 49.43%
2014-12-31 $0.11B $0.06B 58.10%
2014-09-30 $0.10B $0.06B 57.28%
2014-06-30 $0.10B $0.06B 57.58%
2014-03-31 $0.09B $0.05B 54.26%
2013-12-31 $0.08B $0.03B 42.67%
2013-09-30 $0.08B $0.03B 38.96%
2013-06-30 $0.07B $0.03B 33.78%
2013-03-31 $0.07B $0.02B 30.14%
2012-12-31 $0.07B $0.02B 27.78%
2012-09-30 $0.07B $0.02B 25.37%
2012-06-30 $0.07B $0.02B 27.14%
2012-03-31 $0.07B $0.02B 25.76%
2011-12-31 $0.06B $0.02B 23.44%
2011-09-30 $0.06B $0.01B 19.67%
2011-06-30 $0.06B $0.01B 15.79%
2011-03-31 $0.06B $0.01B 12.73%
2010-12-31 $0.06B $0.01B 12.73%
2010-09-30 $0.05B $0.01B 13.73%
2010-06-30 $0.05B $0.01B 14.58%
2010-03-31 $0.04B $0.01B 13.64%
2009-12-31 $0.04B $0.01B 14.63%
2009-09-30 $0.04B $0.01B 12.82%
2009-06-30 $0.04B $0.00B 10.81%
2009-03-31 $0.04B $0.00B 11.11%
2008-12-31 $0.04B $0.00B 11.11%
2008-09-30 $0.04B $0.01B 16.22%
2008-06-30 $0.04B $0.01B 19.44%
2008-03-31 $0.03B $0.01B 23.53%
2007-12-31 $0.03B $0.01B 29.03%
2007-09-30 $0.03B $0.01B 25.93%
2007-06-30 $0.03B $0.01B 28.00%
2007-03-31 $0.03B $0.01B 26.92%
2006-12-31 $0.03B $0.01B 25.93%
2006-09-30 $0.03B $0.01B 26.92%
2006-06-30 $0.03B $0.01B 30.00%
2006-03-31 $0.03B $0.01B 31.03%
2005-12-31 $0.03B $0.01B 31.03%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.572B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09